Profile data is unavailable for this security.
About the company
Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.
- Revenue in NOK (TTM)3.99m
- Net income in NOK-87.94m
- Incorporated2003
- Employees--
- LocationLytix Biopharma ASSandakerveien 138OSLO 0484NorwayNOR
- Phone+47 77675500
- Fax+47 77675501
- Websitehttps://www.lytixbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corline Biomedical AB | 25.19m | -1.82m | 220.59m | 13.00 | -- | 2.35 | -- | 8.76 | -0.0841 | -0.0841 | 1.16 | 4.34 | 0.248 | -- | 10.92 | 1,925,385.00 | -1.79 | -5.71 | -1.92 | -6.24 | 113.38 | 128.60 | -7.22 | -38.46 | -- | -89.40 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Lipum AB (publ) | 0.00 | -37.41m | 230.59m | -- | -- | 13.01 | -- | -- | -4.05 | -4.05 | 0.00 | 0.4726 | 0.00 | -- | -- | -- | -159.35 | -127.85 | -206.31 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | 0.2781 | -- | -- | -- | 2.38 | -- | -- | -- |
| Ultimovacs ASA | 0.00 | -189.24m | 238.43m | 27.00 | -- | 0.8534 | -- | -- | -5.50 | -5.50 | 0.00 | 8.12 | 0.00 | -- | -- | 0.00 | -44.08 | -28.80 | -50.02 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0131 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Thor Medical ASA | 0.00 | -5.56m | 247.55m | 1.00 | -- | 0.9104 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -217.17m | 248.42m | 5.00 | -- | 1.40 | -- | -- | -6.54 | -6.54 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -116.46 | -125.17 | -130.53 | -151.70 | -- | -- | -- | -- | -- | -- | 0.0036 | -- | -- | -- | -117.54 | -- | -- | -- |
| Arctic Bioscience AS | 33.75m | -45.51m | 249.89m | 20.00 | -- | 0.9665 | -- | 7.40 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Lumito AB (publ) | 0.00 | -25.97m | 265.91m | 15.00 | -- | 2.56 | -- | -- | -0.125 | -0.125 | 0.00 | 0.4997 | 0.00 | -- | -- | 0.00 | -19.98 | -20.77 | -22.14 | -22.38 | -- | -- | -- | -- | 1.42 | -- | 0.0884 | -- | -- | -- | 4.56 | -- | -- | -- |
| Lytix Biopharma AS | 3.99m | -87.94m | 292.34m | -- | -- | 4.58 | -- | 73.25 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.037 | -- | 0.4091 | -- | -81.63 | -57.34 | -94.30 | -66.09 | -- | -- | -2,203.36 | -4,665.04 | -- | -- | -- | -- | 183.25 | 63.94 | -57.01 | -- | -- | -- |
| Aqua Bio Technology ASA | 13.51m | -1.50m | 292.90m | 2.00 | -- | 13.61 | 338.38 | 21.68 | -0.1599 | -0.1599 | 0.4938 | 0.3673 | 0.3079 | 0.6548 | 9.01 | -- | -3.42 | -80.72 | -6.75 | -125.29 | 66.69 | 5.57 | -11.12 | -965.98 | 0.1044 | 0.611 | 0.7538 | -- | 349.88 | 42.04 | 1.97 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -26.76m | 300.86m | 7.00 | -- | 6.60 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Intervacc AB | 8.07m | -103.50m | 307.90m | 15.00 | -- | 1.29 | -- | 38.18 | -1.47 | -1.47 | 0.1167 | 3.14 | 0.0306 | 3.08 | 1.72 | 534,333.30 | -39.21 | -17.62 | -42.12 | -18.77 | -628.60 | -243.59 | -1,283.24 | -626.90 | 4.38 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Magle Chemoswed Holding AB | 171.08m | 12.31m | 328.22m | 78.00 | 26.67 | 2.02 | 13.02 | 1.92 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Xbrane Biopharma AB | 240.24m | -324.06m | 333.22m | 93.00 | -- | 0.3323 | -- | 1.39 | -1.27 | -1.52 | 0.943 | 0.6516 | 0.3553 | 2.59 | 357.65 | 2,566,979.00 | -47.92 | -40.98 | -82.48 | -67.24 | 14.82 | -- | -134.89 | -364.40 | 1.09 | -- | 0.2466 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Herantis Pharma Oyj | 0.00 | 3.29m | 338.99m | 10.00 | 113.76 | 6.10 | 103.02 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Medivir AB | 7.68m | -89.89m | 343.92m | 10.00 | -- | 1.46 | -- | 44.77 | -1.46 | -1.46 | 0.1127 | 2.09 | 0.0292 | -- | 2.73 | 763,300.00 | -34.22 | -28.91 | -41.03 | -34.77 | -802.20 | -467.42 | -1,170.21 | -675.96 | -- | -- | 0.0585 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Ascelia Pharma AB | 0.00 | -109.98m | 360.09m | 13.00 | -- | 4.97 | -- | -- | -3.20 | -3.20 | 0.00 | 2.13 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -85.53 | -- | -- | -- | -- | -- | -- | -- | 0.0141 | -- | -- | -- | 16.72 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Lytix Biopharma AS's reporting currency: Norwegian Krone NOK
